PARSIPPANY, N.J., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its third quarter financial results after the close of the U.S. markets on Wednesday November 6, 2024. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the question and answer session via telephone, please pre-register here. All registrants will receive dial-in information and a PIN allowing the ...

Pacira BioSciences (PCRX) announced that the Centers for Medicare and Medicaid Services (CMS) has issued a permanent product-specific J-code (J0666) for its lead pain-management drug, Exparel (bupivacaine liposome injectable suspension), to facilitate better insurance coverage for the drug. This new J-code will take effect on Jan. 1, 2025, replacing the existing C-code (C9290), which has been in use since 2019. Please note that J-codes are reimbursement codes used by insurance companies, including Medicare ...

-- New J-code issued by the Centers for Medicare and Medicaid Services expected to standardize and streamline billing and reimbursement -- TAMPA, Fla., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies, today announced that the Centers for Medicare and Medicaid Services (CMS) has established a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J-code for EXPAREL® (bupivacaine lipos ...

Core Viewpoint - Pacira BioSciences' shares dropped 47.7% following a court ruling that invalidated its '495 patent for Exparel, which could lead to generic competition and significantly impact the company's revenue potential [1]. Company Overview - Pacira's flagship product, Exparel, is a long-acting local analgesic launched in 2012, approved for various postsurgical pain management applications [2]. - In the second quarter of 2024, Exparel generated $137 million in net sales, accounting for 77% of Pacira's total revenues for that quarter [6]. Legal Context - The court ruling is part of ongoing litigation against eVenus Pharmaceutical Laboratories, which aims to launch a generic version of Exparel [3]. - eVenus has countered Pacira's lawsuit by claiming the '495 patent is invalid and/or not infringed [4]. Financial Impact - The invalidation of the patent poses a significant risk to Pacira's revenue, as Exparel's sales are crucial for the company's financial health, and other products like Zilretta and iovera have not yet gained significant market traction [6][7]. - Year-to-date, Pacira's shares have declined 65.3%, contrasting with a 3.4% decline in the industry [6]. Future Considerations - Pacira is exploring legal options, including an appellate review at the U.S. Court of Appeals for the Federal Court [7]. - The company asserts that its Exparel franchise is protected by multiple existing patents, with additional infringement suits and patents in progress [8].

TAMPA, Fla., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. District Court for the District of New Jersey has found that the company's U.S. Patent No. 11,033,495 (the '495 patent) is not valid. "We remain steadfast in our belief in the strength and validity of our intellectual property and that eVenus is infringing upon our patents," said Frank D. L ...

| --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Pacira BioSciences 2Q24 Earnings Presentation July 2024 | | | | | | | | | | | | | | | | | Forward-looking statements and where to find additional information Any statements in this presentation about Pacira's future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words "a ...

Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - CEO & Director Charles Reinhart - Chief Financial Officer Tony Molloy - Chief Legal & Compliance Officer Conference Call Participants Gregory Renza - RBC Capital Markets David Amsellem - Piper Sandler Glen Santangelo - Jefferies Gary Nachman - Raymond James Hardik Parikh - J. P. Morgan Leszek Sulewski - Truist Securities Serge Belanger - N ...

View all Key Company Metrics for Pacira here>>> Shares of Pacira have returned -28.5% over the past month versus the Zacks S&P 500 composite's +0.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Pacira (PCRX) reported $178.02 million in revenue for the quarter ended June 2024, representing a year-overyear increase of 5.1%. EPS of $0.89 for the same period compares to $0.78 a year ago. The reported revenue represents ...

Pacira (PCRX) came out with quarterly earnings of $0.89 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.78 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 21.92%. A quarter ago, it was expected that this specialty drugmaker would post earnings of $0.64 per share when it actually produced earnings of $0.62, delivering a surprise of -3.13%. Over the last four quarters, the comp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OR Delaware 51-0619477 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.) ☒ Yes ☐ ...